Overview

Safety, Tolerability and PK of Multiple-ascending Doses of Emodepside

Status:
Completed
Trial end date:
2018-10-15
Target enrollment:
Participant gender:
Summary
The study evaluates safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of emodepside, after administration as a Liquid Service Formulation (LSF), over 10 days, in healthy male caucasian subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Drugs for Neglected Diseases
Collaborators:
Bayer
Bill and Melinda Gates Foundation
Treatments:
Emodepside